RASSF10 is a tumor suppressor gene that plays an important role in regulating embryonic neurogenesis. In developing tissues, it exhibits striking expression in the rhombencephalon and other brain regions. RASSF10 functions through multiple mechanisms including P53 pathway activation, regulation of the Wnt/β-catenin pathway, and modulation of epithelial-mesenchymal transition markers 1 2. At the cellular level, RASSF10 shows cell-cycle-dependent localization to centrosomes during mitosis and suppresses cancer cell proliferation, migration, and invasion while promoting apoptosis and G2/M phase arrest 3. RASS F10 is frequently inactivated through promoter hypermethylation in diverse cancers including glioblastomas, breast cancer, hepatocellular carcinoma, lung cancer, and acute lymphoblastic leukemia 3 4 5 6. In secondary glioblastomas, RASSF10 methylation is an independent prognostic factor associated with reduced progression-free and overall survival 3. RASSF10 methylation status serves as a docetaxel resistance marker in breast and hepatocellular carcinoma, with restoration of RASSF10 expression sensitizing cancer cells to this chemotherapy agent 4 1. These findings position RASSF10 methylation as a potential biomarker for cancer diagnosis, prognosis, and chemotherapy response prediction across multiple malignancies.